— BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of $0.26 per share.
— Revenue was $39.7 million vs. $2.7 million in the fourth quarter of 2018 and targeted revenue of $9.88 million.
— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.
— For full-year 2020, operating cash use is expected to be in the range of $125 million to $150 million and operating expenses are estimated to be between $135 million and $160 million.
— On February 18, 2020, the company announced that the U.S. Food and Drug Administration (FDA) had accepted and filed its new drug application (NDA) for the approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
— BioCryst expects Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to approve its berotralstat drug for the prophylactic treatment of HAE in the second half of 2020.
— BCRX stock rose about 7% in the pre-market trading session.
Most Popular
Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year
Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings
Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop
Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported
Is Zoom Video Communications (ZM) a good investment after Q3 earnings?
Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of
